New York States landmark policies on oversight and compensation for egg donation to stem cell research

Regenerative Medicine

Volumn 7, Issue 3, 2012, Pages 397-408

  Roxland, Beth E ^a  

^a New York State Task Force on Life and the Law   (United States)

Author keywords

donor compensation; Empire State Stem Cell Board (ESSCB); human subjects research; induced pluripotent stem cells (iPSCs); informed consent; oocyte; ovarian hyperstimulation syndrome (OHSS); somatic cell nuclear transfer (SCNT); stem cell research policy; undue inducement

Indexed keywords

BLOATING; COMPENSATION; FINANCIAL MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HUMAN; HUMAN RIGHTS; JUSTICE; KIDNEY INJURY; MEDICAL ETHICS; MEDICOLEGAL ASPECT; OOCYTE DONATION; OOCYTE RETRIEVAL; OVARY HYPERSTIMULATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; STEM CELL RESEARCH; UNITED STATES; ECONOMICS; ETHICS; FEMALE; GOVERNMENT REGULATION; LEGAL ASPECT; POLICY;

COMPENSATION AND REDRESS; FEMALE; GOVERNMENT REGULATION; HUMANS; NEW YORK; OOCYTE DONATION; ORGANIZATIONAL POLICY; STEM CELL RESEARCH;

EID: 84861324011     PISSN: 17460751     EISSN: 1746076X     Source Type: Journal    
DOI: 10.2217/rme.12.20     Document Type: Review

References (88)

1. Roxland B. Egg donation for stem cell research: how New York State developed its oversight and compensation policies. World Stem Cell Rep. 60-67 (2010).
2. Isasi RM, Knoppers BM. Monetary payments for the procurement of oocytes for stem cell research: in search of ethical and political consistency. Stem Cell Res. 1(1), 37-44 (2007).
3. N.Y. St. Fin. Law § 99-p.
4. N.Y. Pub. Health Law § 265-b(2).
5. N.Y. Pub. Health Law § 265-c(2)(b).
6. American Society of Reproductive Medicine (ASRM) Ethics Committee. Financialcompensation of oocyte donors. Fertil. Steril. 88(2), 305-309 (2006)
7. C.F.R. § 46.101 et. seq.
8. N.Y. Pub. Health Law § 2440 et. seq.
9. Foohey P. Paying women for their eggs for use in stem cell research. Pace L. Rev. 30, 900-926 (2010).
10. Li J, Liu X, Wang H et al. Human embryos derived by somatic cell nuclear transfer using an alternative enucleation approach. Cloning Stem Cells 11(1), 39-50 (2009).
11. Urbach A, Bar-Nur O, Daley GQ, Benvenisty N. Differential modeling of fragile X syndrome and human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell 6, 407-411 (2010).
12. Power C, Rasko JE. Promises and challenges of stem cell research for regenerative medicine. Ann. Intern. Med. 155(10), 706-713 (2011).
13. Robinton DA, Daley GQ. The promise of induced pluripotent stem cells in research and therapy. Nature 481(7381), 295-305 (2012).
14. Steinbrook R. Egg donation and human embryonic stem-cell research. N. Engl. J. Med. 354(4), 324-326 (2006).
15. Institute of Medicine. Assessing the Medical Risks of Human Oocyte Donation for Research: Workshop Report. The National Academies Press, Washington, DC, USA (2007).
16. Ellison B, Meliker J. Assessing the risk of ovarian hyperstimulation syndrome in egg donation: implications for human embryonic stem cell research. Am. J. Bioethics 11(9), 22-30 (2011).
17. Brinton LA. Long-term effects of ovulation-stimulating drugs on cancer risk. Reprod. Biomed. Online 15(1), 38-44 (2007).
18. Ness RB, Cramer DW, Goodman MT et al. Infertility, fertility drugs, and ovarian cancer: a pooled analysis of case-control studies. Am. J. Epidemiol. 155(3), 217-224 (2002).
19. Althuis MD, Moghissi KS, Westhoff CL et al. Uterine cancer after use of clomiphene citrate to induce ovulation. Am. J. Epidemiol. 161(7), 607-615 (2005).
20. Ahuja KK, Simons EG. Cancer of the colon in an egg donor: ethical and policy repercussions for donor recruitment. Hum. Reprod. 13(1), 227-231 (1998).
21. Sauer MV. Defining the incidence of serious complications experienced by oocyte donors: a review of 1000 cases. Am. J. Obstet. Gynecol. 184(3), 277-278 (2001).
22. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyper-stimulation syndrome (OHSS): a review. Hum. Reprod. Update 8(6), 559-577 (2002).
23. Hyun I. Fair payment or undue inducement? Nature 442(7103), 629-630 (2006).
24. Pearson H. Health effects of egg donation may take decades to emerge. Nature 442(7103), 607-608 (2006).
25. Fiore R, Hinsch K. Oocytes for research: reevaluating risks and compensation. Am. J. Bioethics 11(9), 42-43 (2011).
26. Stein A. The conundrum of oocyte donation, human research, OHSS, and ethics. Am. J. Bioethics 11(9), 35-37 (2011).
27. McLeod C, Baylis F. Donating fresh versus frozen embryos to stem cell research: in whose interests? Bioethics 21(9), 465-477 (2007).
28. Tulpule A, Lensch W, Miller JD et al. Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood 115(17), 3453-3462 (2010).
29. Lensch W. Cellular reprogramming and pluripotency induction. Brit. Med. Bull. 90(1), 19-35 (2009).
30. Bercovici M. Biotechnology beyond the embryo: science, ethics, and responsible regulation of egg donation to protect women's rights. Womens Rights L. Reporter 29(4), 193-211 (2008).
31. Carson SA, Esenbach DA, Lomax G, Rice VM, Sauer MV, Taylor RN. Proposed oocyte donation guidelines for stem cell research. Fertil. Steril. 94(7), 2503-2506 (2010).
32. C.F.R. § 46.111(4), 45 C.F.R. §§ 46.116(a)(1)-(8) & (b)(1)-(6).
33. N.Y. Pub. Health Law § 2444.
34. N.Y. Pub. Health Law § 4360, et. seq.
35. N.Y. Comp. Code R. & Regs. § 52-1.1, et. seq.
36. Taylor PL. Comprehensive institutional review of legal, ethical and scientific issues in human embryonic stem cell research, ESCROs and beyond. NYSBA Health L. J. 10(3), 43-55 (2005).
37. Bentley J, Thacker P. The influence of risk and monetary payment on the research participation decision making process. J. Med. Ethics 30(3), 293-298 (2004).
38. Robertson JA. Compensation and egg donation for research. Fertil. Steril. 86(6), 1573-1575 (2006).
39. Halpern SD, Karlawish JH, Casarett D et al. Empirical assessment of whether moderate payments are undue or unjust inducement for participation in clinical trials. Arch. Int. Med. 164(7), 801-803 (2004).
40. Klitzman R, Sauer MV. Payment of egg donors in stem cell research in the USA. Reprod. Biomed. Online 18(5), 603-608 (2009).
41. Veatch R. The Basics of Bioethics (3rd Edition). Pearson Education, NJ, USA, 118 (2012).
42. Grady C. The payment of clinical research subjects. J. Clin. Invest. 115(7), 1681-1687 (2005).
43. Baylis F, McLeod C. The stem cell debate continues. J. Med. Ethics 33(12), 726-731 (2007).
44. Dickenson D. Commodification of human tissue: implications for feminist and development ethics. Dev. World Bioethics 2(1), 55-63 (2002).
45. Skloot R. The Immortal Life of Henrietta Lacks. Crown Publishing Group, NY, USA (2010).
46. Grady D. A lasting gift to medicine that wasn't really a gift. The New York Times, 1 February (2010).
47. Rao R. Coercion, commercialization, and commodification: the ethics of compensation for egg donors in stem cell research. Berkeley Technology L. J. 21(3), 1055-1066 (2006).
48. Levens ED, DeCherney AH. Human oocyte research: the ethics of donation and donor protection. JAMA 300(18), 2174-2176 (2008).
49. Andrews L, Nelkin D. Whose body is it anyway? Disputes over body tissue in a biotechnology age. Lancet 351(9095), 53-57 (1998).
50. Dickenson DL. The lady vanishes: what's missing from the stem cell debate. J. Bioethical Inquiry 3(1-2), 43-54 (2006).
51. Gruen L. Oocytes for sale? Metaphilosophy 38(2-3), 285-308 (2007).
52. Sharp LA. The commodification of the body and its parts. Ann. Rev. Anthro. 29, 287-328 (2000).
53. Crockin SL. A legal defense for compensating research egg donors. Cell Stem Cell 6(2), 99-102 (2010).
54. Baum K. Golden eggs: towards the rational regulation of oocyte donation. Brigh. Young Univ. L. Rev. 1, 107-166 (2001).
55. N.Y. Pub. Health Law § 4307.
56. Cal. Code of Regs. tit. 17 § 100020(h).
57. Egli D, Chen A, Saphier G et al. Impracticality of egg donor recruitment in the absence of compensation. Cell Stem Cell 9(4), 293-294 (2011).
58. Mosher JT, Pemberton TJ, Harter K et al. Lack of population diversity in commonly used hESC lines. N. Engl. J. Med. 362(2), 183-185 (2010).
59. Angel SB. The value of the human egg: an analysis of risk and reward in stem cell research. Berkeley J. Gender Justice 22, 197-198 (2007).
60. Dickert N, Grady C. What's the price of a research subject? Approaches to payment for research participation. N. Engl. J. Med. 341(3), 198-203 (1999).
61. Editorial. Reasonable compensation. The New York Times, 11 July (2009).
62. Ochs R. New York's decision to pay egg donors sparks debate. Newsday, 12 July (2009).
63. Scott CT, McCormick JB, DeRousen MC, Owen-Smith J. Democracy derived? New trajectories in pluripotent stem cell research. Cell Stem Cell 145(6), 820-826 (2011).
64. Grieshammer U, Shepard KA, Nigh EA, Trouson A. Finding the niche for human somatic cell nuclear transfer. Nat. Biotechnol. 29(8), 701-705 (2011).
65. Carvajal-Vergara X, Sevilla A, D'Souza SL et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 465(7308), 808-812 (2010).
66. Lee G, Papapetrou EP, Kim H et al. Modelling pathogenesis and treatment of familial dysautonomia using patient-specific iPSCs. Nature 461(7262), 402-406 (2009).
67. Liu GH, Barko BZ, Ruiz S et al. Recapitulation of premature ageing with iPSCs from Hutchinson-Gilford progeria syndrome. Nature 472(7342), 221-225 (2011).
68. Yazawa M, Hsueh B, Jia X et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 471(7337), 230-234 (2011).
69. Gore A, Li Z, Fung HL et al. Somatic coding mutations in human induced pluripotent stem cells. Nature 471(7336), 58-62 (2011).
70. Mayshar Y, Ben-David U, Lavon N et al. Identification and classification of chromosomal aberrations in human induced pluripotent stem cells. Cell Stem Cell 7(40), 521-531 (2010).
71. Hussein SM, Batada NN, Vuoristo S et al. Copy number variation and selection during reprogramming to pluripotency. Nature 471(7336), 58-62 (2011).
72. Doi A, Park IH, Wen B et al. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat. Genet. 41(12), 1350-1353 (2009).
73. Hu BY, Weick JP, Yu J et al. Neural differentiation of human induced pluripotent stem cells follows developmental principles but with variable potency. Proc. Natl Acad. Sci. USA 107(9), 4335-4340 (2010).
74. Atala A, Becker S, Bishop CE, Choi YH, Chung Y, Dittman R. Reprogramming of human somatic cells using human and animal oocytes. Cloning Stem Cells 11(2), 213-223 (2009).
75. Yu Y, Mai Q, Chen X et al. Assessment of the developmental competence of human somatic cell nuclear transfer embryos by oocyte morphology classification. Hum. Reprod. 24(3), 649-657 (2009).
76. Noggle S, Fung H, Gore A. Human oocytes reprogram somatic cells to a pluripotent state. Nature 478(7367), 70-75 (2011).
77. French AJ, Adams CA, Anderson LS, Kitchen JR, Hughes MR, Wood SH. Development of human cloned blastocysts following somatic cell nuclear transfer with adult fibroblasts. Stem Cells 26(2), 485-493 (2008).
78. Fan Y, Jiang Y, Chen X et al. Derivation of cloned human blastocysts by histone deacetylase inhibitor treatment after somatic cell nuclear transfer with b-thalassemia fibroblasts. Stem Cells Dev. 20(11), 1951-1959 (2011).
79. Kim K, Doi A, Wen B et al. Epigenetic memory in induced pluripotent stem cells. Nature 467(7313), 285-290 (2010).
80. Polo JM, Liu S, Figueroa ME et al. Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nat. Biotechnol. 28(8), 848-857 (2010).
81. Daley G. Triple genomes go far. Nature 478(7367), 40-41 (2011).
82. Hyun I. Moving human SCNT research forward ethically. Cell Stem Cell 9(4), 295-297 (2011).
83. Wade N. After setbacks in harvesting stem cells, a new method shows promise. The New York Times, 6 October (2011).
84. Spar D. The egg trade - making sense of the market for human oocytes. N. Engl. J. Med. 356(13), 1289-1291 (2007).
85. Haimes E, Taylor K, Turkmendag I. Eggs, ethics and exploitation? Investigating women's experiences of an 'egg sharing' scheme. Sociol. Heath Illness (2012) (In press).
86. Egli D, Chen AE, Saphier G. Reprogramming within hours following nuclear transfer into mouse but not human zygotes. Nat. Commun. 2, 488 (2011).
87. van Leeuwen FE, Klip H, Mooij TM et al. Risk of borderline and invasive ovarian tumors after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum. Reprod. 26(12), 3456-3465 (2011).
88. Bamford R. Reconsidering risk to women: oocyte donation for human embryonic stem cell research. Am. J. Bioethics 11(9), 37-39 (2011).